Q-omics provides the consensus-scored MMP20 profile across patient tissues and cancer cell-line models. MMP20 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MMP20 is differentially expressed in 11, with the highest sampling consensus in BRCA. Additionally, MMP20 RNA expression shows 6,949 significant pathway-activity associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, and BRCA as cancer lineages where MMP20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MMP20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MMP20 survival associations across molecular data types. MMP20 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MMP20 RNA expression–survival associations across cancer types. High MMP20 expression shows unfavorable associations in ACC, KIRP, CESC, LIHC, LGG and PCPG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MMP20 RNA expression.
This table summarizes MMP20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MMP20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MMP20 shows lower tumor expression in BRCA and KIRP and higher tumor expression in COAD, LUSC, THCA and LUAD. The BRCA box plot shows higher MMP20 RNA expression in normal versus tumor tissue (log2 FC = −0.493, t-test p < 0.001).
This table shows molecular features associated with MMP20 in patient tissues and cancer cell lines. In patient samples, MMP20 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, MMP20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
